Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine vs Vinorelbine in Pre-Treated Metastatic Breast Cancer
NCT00049660Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2002
- Primary completion
- Dec 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of capecitabine in breast cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Response Rate, Overall Survival and 1 more. Started Sep 2002; status: terminated.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00049660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049660.